Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Autor: Metaxas, Y., Früh, M., Eboulet, E.I., Grosso, F., Pless, M., Zucali, P.A., Ceresoli, G.L., Mark, M., Schneider, M., Maconi, A., Perrino, M., Biaggi-Rudolf, C., Froesch, P., Schmid, S., Waibel, C., Appenzeller, C., Rauch, D., von Moos, R.
Zdroj: In Annals of Oncology April 2020 31(4):495-500
Databáze: ScienceDirect